Co-Diagnostics to Host Investor Conference Amid Regulatory Hurdles — Co-Diagnostics, Inc. (Co-Dx)

Event summary

Co-Diagnostics to host press conference on September 16, 2026, at 10:30 a.m. ET in New York.
CEO Dwight Egan to deliver presentation followed by Q&A session.
Company's Co-Dx PCR at-home and point-of-care platform still under regulatory review.
Event open to media, analysts, and investors in person or via live webcast.

The big picture

Co-Diagnostics' press conference comes at a critical juncture as it navigates regulatory challenges for its at-home and point-of-care diagnostic platform. The event will be closely watched for updates on regulatory progress and strategic direction in a market increasingly dominated by established players and emerging competitors. The company's ability to articulate a clear path to commercialization will be key to maintaining investor confidence.

What we're watching

Regulatory Approval: The pace at which Co-Diagnostics secures regulatory approval for its Co-Dx PCR platform will determine its market entry timing and competitive positioning.
Market Strategy: How Co-Diagnostics plans to differentiate itself in the crowded molecular diagnostics space amid ongoing regulatory hurdles.
Investor Sentiment: Whether the company can reassure investors about its path to commercialization and revenue growth during the press conference.